Nephrotoxicity of Lithium and Drugs of Abuse

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Lithium-induced nephrotoxicity is of little clinical consequence in most patients, especially if maintenance serum levels are kept at the lower end of the therapeutic range. However, it appears that advanced renal failure may develop in a susceptible subgroup of patients on maintenance lithium therapy after decades of treatment. Identification and characterization of this susceptible subgroup remain elusive. Moreover, data are contradictory as to whether it is chronic tubulointerstitial injury or glomerular injury that is primarily responsible for the development of advanced renal failure in a minority of lithium-treated patients. Because nephrotoxicity may be associated with clinical episodes of lithium intoxication or elevated serum lithium levels, an effort should be made to maintain the lowest therapeutic serum lithium level. Isolated polyuria due to impaired concentrating ability may respond to amiloride. A modest reduction in glomerular filtration rate or mildly impaired urinary concentrating ability may not necessarily be a forerunner of progressive renal failure. However, renal function should be monitored regularly, and the risks of nephrotoxicity for individual patients must be weighed against the therapeutic benefit from continued lithium therapy.

Original languageEnglish (US)
Title of host publicationRenal Toxicology
PublisherElsevier Inc.
Pages304-339
Number of pages36
Volume14-15
ISBN (Electronic)9780081006122
ISBN (Print)9780081006016
DOIs
StatePublished - Dec 15 2017

Fingerprint

Street Drugs
Lithium
Renal Insufficiency
Therapeutics
Serum
Maintenance
Polyuria
Amiloride
Wounds and Injuries
Glomerular Filtration Rate
Kidney

Keywords

  • Aquaporin
  • CAMP
  • Cocaine
  • Diabetes insipidus
  • Ecstasy
  • Heroin
  • Heroin-associated nephropathy
  • Hyperparathyroidism
  • Lithium
  • Renal tubular acidosis
  • Rhabdomyolysis
  • Solvent abuse
  • Toluene abuse

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neugarten, J., Friedman, B., & Golestaneh, L. (2017). Nephrotoxicity of Lithium and Drugs of Abuse. In Renal Toxicology (Vol. 14-15, pp. 304-339). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-801238-3.02057-2

Nephrotoxicity of Lithium and Drugs of Abuse. / Neugarten, Joel; Friedman, B.; Golestaneh, Ladan.

Renal Toxicology. Vol. 14-15 Elsevier Inc., 2017. p. 304-339.

Research output: Chapter in Book/Report/Conference proceedingChapter

Neugarten, J, Friedman, B & Golestaneh, L 2017, Nephrotoxicity of Lithium and Drugs of Abuse. in Renal Toxicology. vol. 14-15, Elsevier Inc., pp. 304-339. https://doi.org/10.1016/B978-0-12-801238-3.02057-2
Neugarten J, Friedman B, Golestaneh L. Nephrotoxicity of Lithium and Drugs of Abuse. In Renal Toxicology. Vol. 14-15. Elsevier Inc. 2017. p. 304-339 https://doi.org/10.1016/B978-0-12-801238-3.02057-2
Neugarten, Joel ; Friedman, B. ; Golestaneh, Ladan. / Nephrotoxicity of Lithium and Drugs of Abuse. Renal Toxicology. Vol. 14-15 Elsevier Inc., 2017. pp. 304-339
@inbook{ff7cea6de4ff42d9bdd3827fc94e8fd8,
title = "Nephrotoxicity of Lithium and Drugs of Abuse",
abstract = "Lithium-induced nephrotoxicity is of little clinical consequence in most patients, especially if maintenance serum levels are kept at the lower end of the therapeutic range. However, it appears that advanced renal failure may develop in a susceptible subgroup of patients on maintenance lithium therapy after decades of treatment. Identification and characterization of this susceptible subgroup remain elusive. Moreover, data are contradictory as to whether it is chronic tubulointerstitial injury or glomerular injury that is primarily responsible for the development of advanced renal failure in a minority of lithium-treated patients. Because nephrotoxicity may be associated with clinical episodes of lithium intoxication or elevated serum lithium levels, an effort should be made to maintain the lowest therapeutic serum lithium level. Isolated polyuria due to impaired concentrating ability may respond to amiloride. A modest reduction in glomerular filtration rate or mildly impaired urinary concentrating ability may not necessarily be a forerunner of progressive renal failure. However, renal function should be monitored regularly, and the risks of nephrotoxicity for individual patients must be weighed against the therapeutic benefit from continued lithium therapy.",
keywords = "Aquaporin, CAMP, Cocaine, Diabetes insipidus, Ecstasy, Heroin, Heroin-associated nephropathy, Hyperparathyroidism, Lithium, Renal tubular acidosis, Rhabdomyolysis, Solvent abuse, Toluene abuse",
author = "Joel Neugarten and B. Friedman and Ladan Golestaneh",
year = "2017",
month = "12",
day = "15",
doi = "10.1016/B978-0-12-801238-3.02057-2",
language = "English (US)",
isbn = "9780081006016",
volume = "14-15",
pages = "304--339",
booktitle = "Renal Toxicology",
publisher = "Elsevier Inc.",
address = "United States",

}

TY - CHAP

T1 - Nephrotoxicity of Lithium and Drugs of Abuse

AU - Neugarten, Joel

AU - Friedman, B.

AU - Golestaneh, Ladan

PY - 2017/12/15

Y1 - 2017/12/15

N2 - Lithium-induced nephrotoxicity is of little clinical consequence in most patients, especially if maintenance serum levels are kept at the lower end of the therapeutic range. However, it appears that advanced renal failure may develop in a susceptible subgroup of patients on maintenance lithium therapy after decades of treatment. Identification and characterization of this susceptible subgroup remain elusive. Moreover, data are contradictory as to whether it is chronic tubulointerstitial injury or glomerular injury that is primarily responsible for the development of advanced renal failure in a minority of lithium-treated patients. Because nephrotoxicity may be associated with clinical episodes of lithium intoxication or elevated serum lithium levels, an effort should be made to maintain the lowest therapeutic serum lithium level. Isolated polyuria due to impaired concentrating ability may respond to amiloride. A modest reduction in glomerular filtration rate or mildly impaired urinary concentrating ability may not necessarily be a forerunner of progressive renal failure. However, renal function should be monitored regularly, and the risks of nephrotoxicity for individual patients must be weighed against the therapeutic benefit from continued lithium therapy.

AB - Lithium-induced nephrotoxicity is of little clinical consequence in most patients, especially if maintenance serum levels are kept at the lower end of the therapeutic range. However, it appears that advanced renal failure may develop in a susceptible subgroup of patients on maintenance lithium therapy after decades of treatment. Identification and characterization of this susceptible subgroup remain elusive. Moreover, data are contradictory as to whether it is chronic tubulointerstitial injury or glomerular injury that is primarily responsible for the development of advanced renal failure in a minority of lithium-treated patients. Because nephrotoxicity may be associated with clinical episodes of lithium intoxication or elevated serum lithium levels, an effort should be made to maintain the lowest therapeutic serum lithium level. Isolated polyuria due to impaired concentrating ability may respond to amiloride. A modest reduction in glomerular filtration rate or mildly impaired urinary concentrating ability may not necessarily be a forerunner of progressive renal failure. However, renal function should be monitored regularly, and the risks of nephrotoxicity for individual patients must be weighed against the therapeutic benefit from continued lithium therapy.

KW - Aquaporin

KW - CAMP

KW - Cocaine

KW - Diabetes insipidus

KW - Ecstasy

KW - Heroin

KW - Heroin-associated nephropathy

KW - Hyperparathyroidism

KW - Lithium

KW - Renal tubular acidosis

KW - Rhabdomyolysis

KW - Solvent abuse

KW - Toluene abuse

UR - http://www.scopus.com/inward/record.url?scp=85043320104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043320104&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-801238-3.02057-2

DO - 10.1016/B978-0-12-801238-3.02057-2

M3 - Chapter

SN - 9780081006016

VL - 14-15

SP - 304

EP - 339

BT - Renal Toxicology

PB - Elsevier Inc.

ER -